About

About Cellertz Cellertz Bio is an mRNA therapeutics company combining cutting-edge artificial intelligence and physics-based models to unlock the full potential of mRNA medicines. Our proprietary platform systematically explores the vast mRNA sequence space to design optimized mRNA molecules with superior stability, translation efficiency, and protein expression—enabling a new generation of high-performance mRNA therapies. Beyond platform licensing, Cellertz is building a differentiated therapeutic pipeline focused on in vivo immune cell engineering to treat cancer and autoimmune diseases. These programs offer scalable, off-the-shelf alternatives to cell therapies and can be monetized through strategic partnerships, co-development deals, or out-licensing. With a dual business model spanning platform and therapeutic pipeline, Cellertz is uniquely positioned to create value at the intersection of AI, synthetic biology, and next-generation immunotherapy.